“COST-EFFECTIVENESS OF BEVACIZUMAB AND RANIBIZUMAB AS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR PATIENTS WITH EYE DISORDERS: A SYSTEMATIC REVIEW”, kjif, vol. 9, no. 1, pp. 37–53, Apr. 2024, doi: 10.26874/kjif.v9i1.658.